Skip to main content
. 2023 Oct 30;97(11):e00771-23. doi: 10.1128/jvi.00771-23

Fig 2.

Fig 2

RSV preF-specific FcγR binding and Fc-effector functions induced by Ad26.RSV.preF and the Ad26.RSV.preF/RSV preF protein combination vaccine. RSV preF-specific FcγR binding and Fc-effector functions were measured in serum samples collected on days 1 (pre-vaccination), 15, 29, and 183 from participants receiving Ad26.RSV.preF alone (n = 12), the Ad26.RSV.preF/RSV preF protein combination vaccine (n = 42), or placebo (n = 6). (a) FcγR2a, (b) FcγR2b, (c) FcγR3a, and (d) FcγR3b binding, and induction of (e) ADCD, (f) ADNP, (g) ADCP, and (h) ADNKA, reported as GMFI from baseline. Statistical comparisons were performed by analysis of variance (Kruskal-Wallis) with a Benjamini-Hochberg correction for multiple comparisons. Error bars denote 95% CIs. *P ≤ 0.05; **P ≤ 0.01; ***P < 0.001. Ad26, adenovector type 26; ADCD, antibody-dependent complement deposition; ADCP, antibody-dependent cellular phagocytosis; ADNKA, antibody-dependent natural killer cell activation; ADNP, antibody-dependent neutrophil phagocytosis; CI, confidence interval; FcγR, Fcγ receptor; GMFI, geometric mean fold increase; NK, natural killer; preF, pre-fusion conformation-stabilized RSV F protein; RSV, respiratory syncytial virus.